Trials / Active Not Recruiting
Active Not RecruitingNCT06470438
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation), to further assess the safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-88998377 | JNJ-88998377 will be administered. |
Timeline
- Start date
- 2024-05-28
- Primary completion
- 2027-10-29
- Completion
- 2028-12-29
- First posted
- 2024-06-24
- Last updated
- 2026-04-13
Locations
19 sites across 7 countries: China, Italy, Japan, Poland, South Korea, Taiwan, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06470438. Inclusion in this directory is not an endorsement.